New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
07:38 EDTADXSAdvaxis receives patent in Japan
Advaxis announced that it has received a notice of allowance from the Japan Patent Office for a patent application related to the Advaxis proprietary Lm-LLO cancer immunotherapy platform technology. Once issued, this patent will provide protection in Japan until 2029. The claims under the patent cover composition of matter and methods of use for combining Advaxis's proprietary immunogenic, recombinant tLLO fused to full and partial antigens of particular interest to target cancers such as cervical, ovarian, melanoma, lung, and head and neck. The antigens covered under the claims include HPV-related and prostate cancer antigens, which are expressed in cervical and prostate cancer. Several of these claims are already patented in the United States. This patent along with the other issued patents in Japan, provides stronger protection for current and future uses of Advaxis immunotherapies.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:38 EDTADXSAdvaxis to receive $1.7M through NJ NOL program
Advaxis announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $1.7M in cash in mid-December.
November 12, 2014
07:35 EDTADXSAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use